SpectraCell Laboratories has been issued a patent on its cardiovascular test, the Lipoprotein Particle Profileâ„˘ which has been commercially available since 2006.
Online PR News – 08-February-2011 – – SpectraCell Laboratories has recently been awarded a patent on their Lipoprotein Particle Profileâ„˘ (LPP â„˘) test which is used to measure cardiovascular risk. The LPPâ„˘ has been commercially available since 2006, and is a type of advanced cholesterol test that measures lipoprotein subgroups. The LPPâ„˘ gives more accurate estimation of cardiovascular risk compared to a routine cholesterol test.
The patent was awarded for use of a â€śMethod for Analyzing Blood for Lipoprotein Components.â€ť Specifically, the LPPâ„˘ test utilizes a patented analytical ultracentrifugation method for separating lipoprotein subclasses. This separation method for LPPâ„˘ originated at Texas A & M University and was further developed by Dr. Jan Troup, the inventor of LPPâ„˘ technology, who is also a member of SpectraCell's scientific staff.
â€śThe LPPâ„˘ generally doesnâ€™t cost the patient any more than a standard cholesterol test, but it gives the doctor much more relevant and accurate information.â€ť states Dr. Jan Troup, PhD, and Director of Lipid Science for SpectraCell Laboratories. â€śDifferent lipoproteins respond differently to therapy, whether it is statins, fish oils or niacin, for example. The LPPâ„˘ enables the doctor to treat appropriately.â€ť
In recent years, the medical community has discovered that, beyond â€śstandardâ€ť cholesterol tests, an independent factor for heart disease can be determined by measuring the density and number of lipoprotein particles, to which cholesterol is attached. Patients with a normal cholesterol value, but abnormal particle sizes or numbers, can be at serious risk for cardiovascular disease.
In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have â€śnormalâ€ť cholesterol â€“ that is, cholesterol below 200 mg/dL. NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPPâ„˘ test:
1. RLP â€“ (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
2. Lp(a) â€“ a dangerous lipoprotein that contributes to clot formation
3. HDL2b â€“ a type of HDL that indicates how well cholesterol is being cleared from your system
4. Small, dense LDL â€“ easily penetrates vascular wall, causing damage and plaque
The main reason to know NCEP risk factors are that specific lipoproteins respond to specific therapies very differently. The LPPâ„˘ is part of the trend toward more individualized medicine. The LPP test, which is done on a fasting blood sample, is usually covered by insurance. Results typically take 3-5 days. For more information, go to www.spectracell.com.
About SpectraCell Laboratories â€“ SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing such as micronutrient testing, telomere analysis, Omega 3 Index and the Lipoprotein Particle Profileâ„˘ (LPPâ„˘).
SpectraCellâ€™s Lipoprotein Particle Profileâ„˘ is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCellâ€™s LPPâ„˘ directly measures both the size (density) and number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.